Back to Trades
Total Value
$829.9K
Filing Date
Apr 8, 2026
1 transaction
Trade Summary
On Apr 2, 2026, Menu Philippe, Chief Medical Officer, reported $829.9K of SOPHiA GENETICS SA (SOPH) across 1 transaction. The filing covers Ordinary Shares and reflects balanced net activity of $0. Reported prices ranged from $5.04. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- SOPHiA GENETICS SA
- Ticker Symbol
- SOPH
- CIK
- 0001840706
Insider Information
- Name
- Menu Philippe
- Role
- Chief Medical Officer
Filing Details
- Filing Date
- Apr 8, 2026
- Transaction Date
- Apr 2, 2026
- Accession Number
- 0001840706-26-000106
- Form Type
- 4
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Apr 2, 2026 | Ordinary Shares | 112,936 | — | Grant/Award | — |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Apr 2, 2026 | SOPH derivative | 164,671 | $5.04 | Grant/Award | $829.9K |
Want live alerts when Menu Philippe trades again?
Download Insider Trades to track SOPH, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.
- (F2)This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 112,936 ordinary shares due to an inadvertent error. The correct amount is 286,552 ordinary shares.
- (F3)The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.